Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Cosette Pharmaceuticals, Inc.

Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Appoints Brad Leonard as Vice President, Generics Commercial Operation
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US Market
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Tickers PTN
Cosette Pharmaceuticals Launches Metronidazole Vaginal Gel 0.75%, AB-rated to MetroGel-Vaginal® 0.75%
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone® 5%
From Cosette Pharmaceuticals, Inc.
Via Business Wire
EY Announces Apurva Saraf, President and CEO of Cosette Pharmaceuticals as an Entrepreneur Of The Year® 2023 New Jersey Award Winner
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Appoints Kevin Hickey, Vice President, Brand Sales and Marketing to Accelerate Transformation
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Receives U.S. Patent (US 11,291,628) For Welchol® Chewable Bar, A Novel Oral Drug Delivery System to Deliver Colesevelam Hcl
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva® (Docosanol Cream 10%) Including the First Approval in the Pump Format
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Launches First Injectable Product - Prochlorperazine Edisylate Injection in the U.S.
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Cosette Pharmaceuticals Acquires Rights to Eight Branded Products from Daiichi Sankyo
From Cosette Pharmaceuticals, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.